# Omeros Forecasts $5 Million to $6 Million in Q4 Discontinued-Operations Income

By John Kim

Canonical URL: https://www.tokenpost.com/news/business/58950
Published: 2026-11-17T01:08:05.000Z
Updated: 2026-11-17T01:08:05.000Z
Section: Business

> YARTEMLEA gross revenue rose 29.6% sequentially in Q3. Medicare’s revised outpatient payment rate for 340B-acquired drugs, including YARTEMLEA, takes effect Jan. 1, 2027.

Omeros Corporation expects $5 million to $6 million in fourth-quarter income from discontinued operations as YARTEMLEA sales grow and outpatient use expands. The forecast excludes noncash remeasurement adjustments tied to the company’s OMIDRIA contract royalty asset.

The forecast compares with $6.5 million in discontinued-operations income in the third quarter. Omeros also posted a $57.4 million net loss under generally accepted accounting principles (GAAP) for the quarter. That result included a $62.0 million noncash loss, primarily related to mark-to-market adjustments of a derivative associated with the company’s 2029 convertible notes.

YARTEMLEA, Omeros’ treatment for stem cell transplant-associated thrombotic microangiopathy (TA-TMA), generated $41.8 million in gross revenue in the third quarter, up 29.6% from the previous quarter. Net revenue increased 26% to $35.9 million.

Omeros added 10 field education positions, including a six-member clinical nurse educator team, to support transplant teams. Outpatient use increased alongside purchases by entities covered by the 340B Drug Pricing Program. Medicare’s revised outpatient payment rate for 340B-acquired drugs, including YARTEMLEA, takes effect Jan. 1, 2027.


